BC diagnoses in older patients (pts) are rising as population demographics change and life expectancy increases. The multinational TEAM study (N = 9,766) reported worse outcomes for older pts with HR+ BC (JAMA. 2012;307:590). To confirm this finding and to examine the role of tumor biology, SEER and Genomic Health collaborated to electronically supplement SEER registries with RS results and evaluate BC-specific mortality (BCSM).
21-gene RS results were provided to the NCI-sponsored SEER registries and linked to SEER BC cases. Eligible pts were diagnosed (Jan 2004 – Dec 2011) with N0 HR+ BC, and had no prior malignancy or multiple tumors. BCSM, defined previously (JNCI. 2010;102:1584), was analyzed separately for pts
Of 184,190 eligible pts, 70%/30% were 1-2 cm). Reported chemotherapy (CT) use and 5-y BCSM are shown in Table. CT use was lower for pts ≥70 y (p
This large population-based observational study of N0 HR+ BC shows that unacceptably high BCSM persists in US clinical practice for pts ≥70 y with either no 21-gene assay done or an RS ≥18 (but not RS
Clinical trial identification
Legal entity responsible for the study
Steven Shak, Dave P. Miller, Lynne Penberthy, Valentina I. Petkov
National Cancer Institute
S. Shak, D.P. Miller, N. Gliner, F.L. Baehner: Employed by Genomic Health; stock ownership in Genomic Health. All other authors have declared no conflicts of interest.